An observational study in Spinal Dural Arteriovenous Fistula, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Thomas Jefferson University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Arteriovenous Fistula with a site in United States — 6 open to participants now, 11 under way, none of them phase 3. Arteriovenous Fistula · United States.
Among the 60 studies in Arteriovenous Fistula with a site in United States, this one is the 2nd largest by planned enrollment of the 15 observational ones that give a count, is the only one that started in 2026, is one of 15 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 60th registered.
248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.
Browse Arteriovenous Fistula studies →6 of the 60 studies in Arteriovenous Fistula with a site in United States are open now. Recruiting first, the newest first:
Venova Medical · Sites in United States
Ages 18–80
Merit Medical Systems, Inc. · Sites in United States, Canada
Ages 18+
VenoStent · Sites in United States
Ages 18+
C. R. Bard · Sites in United States, Australia
Ages 18+
Alejandro Berenstein · Sites in United States
Ages up to 21
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 1
First in 1993; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 100 across 71 observational studies indexed under Arteriovenous Fistula.
Median enrollment 65 across the 45 interventional studies, 60 across the 15 observational. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 60 have an industry lead sponsor. The 10 most frequent:
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
Thomas Jefferson University has 1 study filed under Arteriovenous Fistula — fewer than ten, so there is no comparison to draw.
3 of the studies in Arteriovenous Fistula with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03506308C. R. BardPost Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae | 2027-04 |
| NCT04634916C. R. BardPost-market Surveillance Study of the BD® WavelinQ™ EndoAVF System | 2027-06 |
| NCT06001827VenoStentSAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 60 studies in Arteriovenous Fistula with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Given the lack of large multicenter datasets in the context of Spinal arteriovenous fistula, the strength of the evidence surrounding this rare disease is limited. SPIDER hence aims to address that by compiling patient-level data from centers all around the world.
Type 1 or dural spinal arteriovenous fistulas (SDAVFs) are the most common spinal vascular malformation but remain frequently underdiagnosed due to their insidious onset and nonspecific clinical presentation. Delayed diagnosis is common and often results in progressive, and sometimes irreversible, myelopathy. Despite advances in imaging and treatment, there remains significant variability in diagnostic timelines, treatment strategies (endovascular, surgical, or combined), and reported outcomes across institutions.
Existing literature is largely limited to single-center retrospective series or small cohorts, often underpowered to evaluate predictors of outcome, recurrence, and the impact of diagnostic delay. Furthermore, direct comparisons between treatment modalities and long-term functional outcomes using standardized clinical scales are limited.
The SPIDER registry is designed to address these gaps by creating the largest international, multicenter dataset of patients with spinal dural AVFs. By pooling de-identified data from high-volume centers worldwide, this study aims to provide robust, generalizable evidence to inform clinical decision-making and optimize patient outcomes.
The registry will include patients from 40 different hospitals in 20 different countries.
Inclusion Criteria:
Treatment success
Complete surgical/endovascular obliteration of the fistula
Time frame: Recorded at the end of the embolization or surgery.
Recurrence
Fistula recurrence
Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.
Status of symptoms at last clinical follow-up
Improved, unchanged, or worsened pain, sensory, and motor symptoms
Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.
Modified Aminoff-Logue Scale
Gait and bowel/bladder score
Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.
Modified Rankin Scale
Measure of functional independence
Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.
Mortality
Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.
Plan to share: No — Data cannot be shared due to its multicenter nature.
Started Jan 2026 (actual). Primary completion is estimated for May 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.